Dr. Clay Seigall has a long history in the pharmaceutical business. He served at the National Institute of Health and the National Cancer Institute from 1988 to 1991. From 1991 to 1997 he worked for Bristol-Myers Pharmaceutical Research Institute. In 1988 he co-founded Seattle Genetics, Inc. and is today the company’s Chief Executive Officer, President, and serves as a member on the Board of Directors.
Under Dr. Seigall’s leadership Seattle Genetics has developed a portfolio of cancer and autoimmune drugs that are in either the clinical or preclinical stages. It’s most noteworthy drug is Adcetris, an antibody-drug conjugate that is a treatment for patients with Hodgkin Lymphoma and systemic anaplastic large cell lymphoma. In a 2010 clinical trial 34% of patients being treated for Hodgkin Lymphoma achieved complete remission and 40% had partial remission. The drug has been used to treat over 15,000 Hodgkin Lymphoma patients worldwide. Other cancer drugs that Seattle Genetics has made large investments into researching include their two lead pipeline drugs, SGN-CD33A to treat acute myeloid leukemia and SGN-CD19A which is for the treatment of non Hodgkin Lymphoma. Beyond that they have five other clinical-stage programs in development. In developing their drugs Seattle Genetics has at times collaborated with a number of well known pharmaceutical companies. Among these would be Bayer, GlaxoSmithKline, Takeda Pharmaceutical Company, and Pfizer.
As Chief Executive Officer of Seattle Genetics, Dr. Seigall has the responsibility of making major corporate decisions. He also oversees overall operations of the company and sets its vision and goals. It is his responsibility to plan and implement the strategic direction of the company, and is a role that Dr. Seigall has shown he is more than able to do in expertly guiding Seattle Genetics over the last 15 years.